EA200971017A1 - Аминоалкоксиарилсульфонамидные соединения и их применение в качестве 5-нтлигандов - Google Patents

Аминоалкоксиарилсульфонамидные соединения и их применение в качестве 5-нтлигандов

Info

Publication number
EA200971017A1
EA200971017A1 EA200971017A EA200971017A EA200971017A1 EA 200971017 A1 EA200971017 A1 EA 200971017A1 EA 200971017 A EA200971017 A EA 200971017A EA 200971017 A EA200971017 A EA 200971017A EA 200971017 A1 EA200971017 A1 EA 200971017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
disorders
pharmaceutically acceptable
ntligand
aminoaloxyaryalsulphonamide
Prior art date
Application number
EA200971017A
Other languages
English (en)
Other versions
EA016594B1 (ru
Inventor
Рамакришна Нироджи
Рама Састри Камбхампати
Анил Карбхари Схинде
Ананд Виджайкумар Даулатабад
Ади Редди Дварампуди
Нагарадж Вишвоттам Кандикере
Сантош Вишвакарма
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA200971017A1 publication Critical patent/EA200971017A1/ru
Publication of EA016594B1 publication Critical patent/EA016594B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Настоящее изобретение относится к новым аминоалкоксиарилсульфонамидным соединениям формулы (I), их производным, стереоизомерам, фармацевтически приемлемьм солям и содержащим их фармацевтически приемлемым композициям. Настоящее изобретение также относится к способам получения указанных выше новых соединений, их производных, стереоизомеров, фармацевтически приемлемых солей и содержащих их фармацевтически приемлемых композиций. Данные соединения полезны для лечения различных расстройств, которые связаны с функцией рецептора 5-НТ. Конкретно, соединения настоящего изобретения также полезны для лечения различных расстройств ЦНС, гематологических расстройств, расстройств пищевого поведения, заболеваний, связанных с болью, респираторных заболеваний, генито-урологических расстройств, сердечно-сосудистых заболеваний и рака.
EA200971017A 2007-05-03 2008-04-15 Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов EA016594B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN940CH2007 2007-05-03
PCT/IN2008/000247 WO2008136017A1 (en) 2007-05-03 2008-04-15 Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
EA200971017A1 true EA200971017A1 (ru) 2010-04-30
EA016594B1 EA016594B1 (ru) 2012-06-29

Family

ID=39743760

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971017A EA016594B1 (ru) 2007-05-03 2008-04-15 Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов

Country Status (21)

Country Link
US (1) US8003670B2 (ru)
EP (1) EP2155674B1 (ru)
JP (1) JP5139512B2 (ru)
KR (1) KR101162482B1 (ru)
CN (1) CN101675032B (ru)
AT (1) ATE513810T1 (ru)
AU (1) AU2008246947B2 (ru)
BR (1) BRPI0809873A2 (ru)
CA (1) CA2683124C (ru)
CY (1) CY1111836T1 (ru)
DK (1) DK2155674T3 (ru)
EA (1) EA016594B1 (ru)
ES (1) ES2366496T3 (ru)
HK (1) HK1138264A1 (ru)
HR (1) HRP20110530T1 (ru)
IL (1) IL201491A (ru)
MX (1) MX2009011461A (ru)
NZ (1) NZ581580A (ru)
SI (1) SI2155674T1 (ru)
WO (1) WO2008136017A1 (ru)
ZA (1) ZA200907015B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101337003B1 (ko) 2012-02-13 2013-12-04 주식회사 평산 링 압연 공법을 이용한 풍력 타워용 플랜지 제조방법
KR101338954B1 (ko) 2012-02-13 2013-12-09 주식회사 평산 링 압연 공정을 이용한 비대칭 단면을 가지는 제품의 성형 장치 및 성형 방법
CN105531272B (zh) 2013-07-25 2017-12-22 雅盖隆大学 作为5‑ht6拮抗剂的吡咯并喹啉衍生物、其制备方法和用途
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
WO2019180176A1 (en) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition for the treatment of schizophrenia and/or psychosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
JP2002511097A (ja) 1997-07-11 2002-04-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
ATE375990T1 (de) 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
BR0115102B1 (pt) 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
DE60214990T2 (de) 2001-01-30 2007-04-05 Eli Lilly And Co., Indianapolis Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
ES2280546T3 (es) 2001-06-07 2007-09-16 F. Hoffmann-La Roche Ag Nuevos derivados de indol con afinidad por el receptor 5-ht6.
US20040242589A1 (en) 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
AU2003238339A1 (en) 2002-02-01 2003-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
AU2003244452A1 (en) 2002-02-05 2003-09-02 Glaxo Group Limited Method of promoting neuronal growth
JP4455064B2 (ja) 2002-03-27 2010-04-21 グラクソ グループ リミテッド キノリン誘導体および５−ｈｔ６リガンドとしてのその使用
NZ540842A (en) * 2002-11-28 2008-05-30 Suven Life Sciences Ltd N-arylsulfonyl-3-aminoalkoxyindoles
AU2003292508A1 (en) 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
DK1581538T3 (da) 2002-12-18 2007-06-25 Suven Life Sciences Ltd Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
MXPA05006650A (es) * 2002-12-20 2005-09-30 Cancer Rec Tech Ltd Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
EP1919896B1 (en) * 2005-08-12 2009-12-23 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.

Also Published As

Publication number Publication date
EA016594B1 (ru) 2012-06-29
BRPI0809873A2 (pt) 2018-11-13
ATE513810T1 (de) 2011-07-15
ES2366496T3 (es) 2011-10-20
CN101675032A (zh) 2010-03-17
JP5139512B2 (ja) 2013-02-06
NZ581580A (en) 2011-03-31
US8003670B2 (en) 2011-08-23
SI2155674T1 (sl) 2011-10-28
KR101162482B1 (ko) 2012-07-03
KR20100007954A (ko) 2010-01-22
WO2008136017A1 (en) 2008-11-13
AU2008246947A1 (en) 2008-11-13
ZA200907015B (en) 2010-07-28
IL201491A (en) 2015-04-30
MX2009011461A (es) 2009-11-10
CN101675032B (zh) 2012-10-31
EP2155674A1 (en) 2010-02-24
JP2010526057A (ja) 2010-07-29
US20100087484A1 (en) 2010-04-08
CA2683124C (en) 2012-09-25
HRP20110530T1 (hr) 2011-09-30
HK1138264A1 (en) 2010-08-20
AU2008246947B2 (en) 2011-03-31
CY1111836T1 (el) 2015-10-07
DK2155674T3 (da) 2011-09-26
EP2155674B1 (en) 2011-06-22
CA2683124A1 (en) 2008-11-13
IL201491A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
EA200971017A1 (ru) Аминоалкоксиарилсульфонамидные соединения и их применение в качестве 5-нтлигандов
CY1111105T1 (el) Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6
CY1112181T1 (el) Αμινο αρυλοσουλφοναμιδικες ενωσεις και η χρηση τους ως 5-ητ6 συνδετες
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU